BioSpace News Archive

Roche Could Take a $500M Hit Over Patent Losses

Business

Suitors Take Note as Bay Area’s Nektar May Be Up for Sale

Nektar is reportedly exploring various strategic options, including a possible sale, partnerships or licensing agreements.

February 5, 2018

·

2 min read

·

Mark Terry

Why Bristol-Myers' Future is Highly Dependent on T

Drug Development

Bristol-Myers’ Lung Cancer Opdivo-Yervoy Combo Wows in Phase III Study

BMS shares climb more than 4% this morning after the company announced its anticipated Phase III CheckMate-227 study data.

February 5, 2018

·

3 min read

·

Alex Keown

Amneal and Impax to Marry, Creating the 5th Larges

Genetown

3 High-Risk Biotechs That Could Pop or Drop in 2018

A look at three biotech companies that face make-or-break catalysts this year.

February 5, 2018

·

3 min read

·

Mark Terry

Drug Development

Genentech’s Tecentriq Impresses Again in Late-Stage Kidney Cancer Trial

Genentech said the Phase III combination therapy improved progression-free survival by 26 percent in mRCC patients whose disease expressed a PD-L1 protein.

February 5, 2018

·

2 min read

·

Alex Keown

Deals

GSK, Reckitt are the Only Suitors for Pfizer’s $20B Consumer Health Biz

Companies including Sanofi, J&J, Nestle have dropped out.

February 5, 2018

·

1 min read

3 Biotechs That Got Huge Boosts From Spark's FDA P

Genetown

The 3 Small CRISPR Biotechs That Could Cure 10,000 Diseases

A look at three small biotech companies that appear to be leading the CRISPR race.

February 5, 2018

·

3 min read

·

Mark Terry

Week in Review: C-Bridge Raising Another $650M for China Healthcare

Shanghai’s C-Bridge Capital plans to raise $650M for its third healthcare PE fund, just six months after closing its second fund with $400M.

February 5, 2018

·

1 min read

Drug Development

Astellas, Pfizer’s Prostate Cancer Drug Slays in Phase III Study

Late-stage data shows the use of Pfizer’s prostate cancer drug Xtandi plus ADT significantly reduced the risk of developing metastases or death by 71 percent.

February 5, 2018

·

2 min read

·

Alex Keown

JHL Shareholders Approve Voluntary De-Listing from Taiwan Exchange

The shareholders of JHL Biotech voted to approve the company’s voluntary delisting from the Taiwan stock exchange.

February 5, 2018

·

1 min read